Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma

Cancer

Volumn 106, Issue 7, 2006, Pages 1602-1609

  Hou, Peng ^a   Ji, Meiju ^a   Yang, Bin ^a   Chen, Zaozao ^a   Qiu, Junjun ^b   Shi, Xin ^b   Lu, Zuhong ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Hypermethylation; Multiple genes; Osteosarcoma; Quantitative methylation specific polymerase chain reaction

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADOLESCENT; ADULT; ARTICLE; CPG ISLAND; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; ONCOGENE RAS; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHOOL CHILD;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, NEOPLASM; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS);

EID: 33645830723     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21762     Document Type: Article

References (48)

1. Birch JM, Alston RD, Quinn M, et al. Incidence of malignant disease by morphological type, in young persons aged 12-24 years in England, 1979-1997. Eur J Cancer. 2003;39:2622-2631.
2. Cotterill SJ, Wright CM, Pearce MS, et al. Stature of young people with malignant bone tumors. Pediatr Blood Cancer. 2004;42:59-63.
3. Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncol. 2005;6:85-92.
4. Tsuchiya T, Sekine K, Hinohara S, et al. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 2000;120:91-98.
5. Benassi MS, Molendini L, Gamberi G, et al. Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma. Cancer. 2001;92:3062-3067.
6. Benassi MS, Molendini L, Gamberi G, et al. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer. 1999;84:489-493.
7. Lim S, Yang MH, Park JH, et al. Inactivation of the RASSF1A in osteosarcoma. Oncol Rep. 2003;10:897-901.
8. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 2002;21:4345-4349.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
10. Warnecke PM, Bestor TH. Cytosine methylation and human cancer. Curr Opin Oncol. 2000;12:68-73.
11. Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocr Relat Cancer. 2001;8:115-127.
12. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene. 2002;21:5462-5482.
13. Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann Surg. 2001;234:10-20.
14. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-428.
15. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225-3229.
16. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999;59:3730-3740.
17. Fackler MJ, Evron E, Khan SA, et al. Novel agents for chemoprevention, screening methods, and sampling issues. J Mammary Gland Biol Neoplasia. 2003;8:75-89.
18. Zou HZ, Yu BM, Wang ZW, et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res. 2002;8:188-191.
19. Kobayashi K, Ouchida M, Tsuji T, et al. Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene. 2002;282:151-158.
20. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-9826.
21. Hou P, Ji MJ, Shen JY, et al. Detection of p16 hypermethylation in gastric carcinomas using a seminested methylation-specific PCR. Biochem Genet. 2005;43:1-9.
22. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000;60:5954-5858.
23. Buller A, Pandya A, Jackson-Cook C, et al. Validation of a multiplex methylation-sensitive PCR assay for the diagnosis of Prader-Willi and Angelman's syndromes. Mol Diagn. 2000;5:239-243.
24. Brock MV, Gou M, Akiyama Y, et al, Montgomery E, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003;9:2912-2919.
25. Lehmann U, Langer F, Feist H, et al. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol. 2002;160:605-612.
26. Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 1999;59:2302-2306.
27. Lo YM, Wong IH, Zhang J, et al. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 1999;59:3899-3903.
28. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000;28:E32.
29. Trinh BN, Long TI, Laird PW. DNA Methylation analysis by MethyLight technology. Methods. 2001;25:456-462.
30. Lehmann U, Hasemeier B, Lilischkis R, et al. Quantitative analysis of promoter hypermethylation in laser-microdissected archival specimens. Lab Invest. 2001;81:635-638.
31. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology. 2002;60:1131-1135.
32. Xing M, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 2004;64:1664-1668.
33. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. 2004;363:1283-1285.
34. Hoque MO, Begum S, Topaloglu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004;64:5511-5517.
35. Brock MV, Gou M, Akiyama Y, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003;9:2912-2919.
36. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225-3229.
37. 6- methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer. 2001;92:2760-2768.
38. Gustafson KS, Furth EE, Heitjan DF, et al. DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens: an approach that utilizes receiver-operating characteristic analysis. Cancer. 2004;102:259-268.
39. Laird PW, Zijderveld A, Linders K, et al. Simplified mammalian DNA isolation procedure. Nucleic Acids Res. 1991;19:4293.
40. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA. 1992;89:1827-1831.
41. Clark SJ, Harrison J, Paul CL, et al. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 1994;22:2990-2997.
42. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054.
43. Bachman KE, Herman JG, Corn PG, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999;59:798-802.
44. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 1990;50:6119-6129.
45. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-1354.
46. Inbal B, Cohen O, Polak-Charcon S, et al. DAK kinase links the control of apoptosis to metastasis. Nature. 1997;390:180-184.
47. 6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001;61:939-942.
48. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in Stage I non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:1511-1216.